Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.190 -0.280 (-6.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Recap: Lantern Pharma Q4 Earnings
 
Via Benzinga
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For March 18, 2024
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Lantern Pharma Earnings Preview
 
Via Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma: Q3 Earnings Insights
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
A Preview Of Lantern Pharma's Earnings
 
Via Benzinga
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. 
Via Benzinga
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
From Lantern Pharma Inc.
Via Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries. 
Via InvestorPlace
Topics Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
From Lantern Pharma
Via Business Wire
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
The 3 Most Undervalued AI Penny Stocks to Buy in December
These AI penny stocks offer substantial returns to investors as the market continues to grow at a rapid pace. 
Via InvestorPlace
Topics Artificial Intelligence
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023
Unlock exponential growth with the next big undervalued AI penny stocks to buy, offering tremendous upside ahead. 
Via InvestorPlace
Topics Artificial Intelligence
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
From Lantern Pharma
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.